|
EP1668143B1
(en)
*
|
2003-09-30 |
2013-03-20 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
CN101528916B
(zh)
|
2006-04-28 |
2013-09-04 |
宾夕法尼亚大学托管会 |
规模可调的aav生产方法
|
|
US9839696B2
(en)
|
2010-04-30 |
2017-12-12 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
BR112015021036A2
(pt)
|
2013-03-15 |
2017-10-10 |
Univ Pennsylvania |
composições e métodos para tratar mps1
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
WO2016200543A2
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
|
|
US10966414B2
(en)
|
2015-05-26 |
2021-04-06 |
California Institute Of Technology |
Population control using engineered translocations
|
|
IL314171A
(en)
|
2015-09-28 |
2024-09-01 |
Univ Florida |
Methods and compositions for antibody-evading virus vectors
|
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
WO2017096164A1
(en)
|
2015-12-02 |
2017-06-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
|
|
US10406244B2
(en)
|
2015-12-02 |
2019-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
AAV vectors with expanded packaging capacity
|
|
US11015174B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV8
|
|
EP3387138B2
(en)
|
2015-12-11 |
2026-05-27 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
EP3992283A1
(en)
|
2015-12-11 |
2022-05-04 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
MA43968A
(fr)
|
2016-02-03 |
2018-12-12 |
Univ Pennsylvania |
Thérapie génique pour traiter la mucopolysaccharidose de type i
|
|
CA3014637A1
(en)
|
2016-02-16 |
2017-08-24 |
Mark A. Kay |
Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
|
|
US11253612B2
(en)
|
2016-04-15 |
2022-02-22 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type II
|
|
WO2017192750A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Oregon Health & Science University |
Recombinant adeno-associated viral vectors
|
|
US10584337B2
(en)
|
2016-05-18 |
2020-03-10 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
JP6994018B2
(ja)
*
|
2016-07-26 |
2022-01-14 |
バイオマリン ファーマシューティカル インコーポレイテッド |
新規アデノ随伴ウイルスキャプシドタンパク質
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
RS65241B1
(sr)
*
|
2017-02-28 |
2024-03-29 |
Univ Pennsylvania |
Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
|
|
TW201837170A
(zh)
|
2017-02-28 |
2018-10-16 |
賓州大學委員會 |
新穎aav媒介的流感疫苗
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
KR20190123328A
(ko)
|
2017-03-09 |
2019-10-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
암 백신
|
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
|
WO2018204722A1
(en)
*
|
2017-05-05 |
2018-11-08 |
Califorinia Institute Of Technology |
Dna sequence modification-based gene drive
|
|
BR112019023303A2
(pt)
|
2017-05-11 |
2020-06-16 |
The Trustees Of The University Of Pennsylvania |
Terapia de gene para lipofuscinoses ceroides neuronais
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
CN107034233B
(zh)
*
|
2017-05-18 |
2021-06-08 |
中国科学院重庆绿色智能技术研究院 |
一种内源性启动子驱动外源基因表达的方法
|
|
US11667934B2
(en)
|
2017-06-15 |
2023-06-06 |
Toolgen Incorporated |
Platform for expressing protein of interest in liver
|
|
CA3068328A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
EP3684938A1
(en)
|
2017-09-22 |
2020-07-29 |
The Trustees of the University of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
US12201657B2
(en)
*
|
2017-10-18 |
2025-01-21 |
City Of Hope |
Adeno-associated virus compositions for restoring HBB gene function and methods of use thereof
|
|
CN107937441B
(zh)
*
|
2017-11-14 |
2021-02-26 |
中国科学院苏州生物医学工程技术研究所 |
AAVS1位点定点整合外源基因的人iPS细胞的构建方法
|
|
EA202091352A1
(ru)
|
2017-11-30 |
2020-08-27 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Генотерапия мукополисахаридоза iiib
|
|
US11555206B2
(en)
|
2017-11-30 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis IIIA
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
WO2019152841A1
(en)
*
|
2018-02-01 |
2019-08-08 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for pah gene transfer and methods of use thereof
|
|
AU2019215152A1
(en)
*
|
2018-02-01 |
2020-08-20 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
|
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
|
EP3768695A4
(en)
*
|
2018-02-27 |
2022-04-06 |
The Trustees of the University of Pennsylvania |
NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS WITH REDUCED CAPSIID DEAMIDATION AND USES THEREOF
|
|
CA3095179A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
BR112020020266A2
(pt)
|
2018-04-03 |
2021-01-19 |
Stridebio, Inc. |
Vetores de vírus com evasão de anticorpos
|
|
MX2020010465A
(es)
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus para direccionamiento a tejidos oftalmicos.
|
|
JP7374119B2
(ja)
|
2018-04-05 |
2023-11-06 |
ジェネトン |
減少した肝臓向性を有するAAV9とAAVrh74とのハイブリッド組換えアデノ随伴ウイルス血清型
|
|
CA3099958A1
(en)
|
2018-04-16 |
2019-10-24 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating duchenne muscular dystrophy
|
|
CA3098566A1
(en)
|
2018-04-29 |
2019-11-07 |
Zhuchun WU |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
KR20210008501A
(ko)
|
2018-05-09 |
2021-01-22 |
바이오마린 파머수티컬 인크. |
페닐케톤뇨증을 치료하는 방법
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
CN112424359A
(zh)
|
2018-05-15 |
2021-02-26 |
沃雅戈治疗公司 |
用于治疗帕金森氏病的组合物和方法
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
IL319002A
(en)
|
2018-06-14 |
2025-04-01 |
Regenxbio Inc |
Anion exchange chromatography for recombinant AAV production
|
|
US20210254103A1
(en)
*
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
EP3820495A4
(en)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
|
|
WO2020033842A1
(en)
|
2018-08-10 |
2020-02-13 |
Regenxbio Inc. |
Scalable method for recombinant aav production
|
|
MX2021001850A
(es)
|
2018-08-18 |
2021-07-15 |
Harvard College |
Edicion genica in situ.
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
EP3860659A1
(en)
|
2018-10-01 |
2021-08-11 |
The Trustees of the University of Pennsylvania |
Compositions useful for treating gm1 gangliosidosis
|
|
AU2019354296A1
(en)
|
2018-10-01 |
2021-04-29 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2022514112A
(ja)
|
2018-10-15 |
2022-02-09 |
リジェネクスバイオ インコーポレイテッド |
複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US11965172B2
(en)
|
2018-11-05 |
2024-04-23 |
California Institute Of Technology |
DNA sequence modification-based gene drive
|
|
KR20210112339A
(ko)
|
2019-01-04 |
2021-09-14 |
울트라제닉스 파마수티컬 인코포레이티드 |
윌슨병을 치료하기 위한 유전자 요법 구축물
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
EP3931337A1
(en)
|
2019-02-26 |
2022-01-05 |
The Trustees of The University of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
WO2020191241A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
ES2965341T3
(es)
|
2019-04-11 |
2024-04-12 |
Regenxbio Inc |
Métodos de cromatografía de exclusión por tamaño para la caracterización de composiciones de virus adenoasociados recombinantes
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
JP7630443B2
(ja)
|
2019-04-19 |
2025-02-17 |
レジェンクスバイオ インコーポレーテッド |
アデノ随伴ウイルスベクター製剤及び方法
|
|
US20220195462A1
(en)
|
2019-04-24 |
2022-06-23 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
JP7715640B2
(ja)
|
2019-05-03 |
2025-07-30 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
異染性白質ジストロフィーの治療に有用な組成物
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
EP4004214A1
(en)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
JP7689949B2
(ja)
|
2019-10-03 |
2025-06-09 |
アーティサン ディベロップメント ラブズ インコーポレイテッド |
操作されたデュアルガイド核酸を有するcrisprシステム
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
MX2022004353A
(es)
|
2019-10-17 |
2022-07-19 |
|
Casete de transferencia de aav.
|
|
CN114787180A
(zh)
|
2019-10-17 |
2022-07-22 |
斯特里迪比奥公司 |
用于治疗c型尼曼-匹克病的腺相关病毒载体
|
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
AU2020392243A1
(en)
|
2019-11-28 |
2022-06-16 |
Regenxbio Inc. |
Microdystrophin gene therapy constructs and uses thereof
|
|
BR112022011916A2
(pt)
|
2019-12-19 |
2022-09-06 |
Univ Pennsylvania |
Composições para tratar a ataxia de friedreich
|
|
CN113122657B
(zh)
*
|
2019-12-31 |
2022-07-29 |
上海吉凯基因医学科技股份有限公司 |
一种多重aav病毒滴度的检测方法
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
WO2021155337A1
(en)
|
2020-02-02 |
2021-08-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treating gm1 gangliosidosis
|
|
AU2021218703A1
(en)
|
2020-02-14 |
2022-07-28 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating CDKL5 deficiency disorder
|
|
US20230140435A1
(en)
*
|
2020-03-16 |
2023-05-04 |
The Trustees Of The University Of Pennsylvania |
Composition and methods for improving heart function and treating heart failure
|
|
US12686874B2
(en)
|
2020-03-31 |
2026-07-21 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
WO2021202651A1
(en)
|
2020-04-01 |
2021-10-07 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
CA3180222A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
AU2021271635A1
(en)
|
2020-05-12 |
2023-01-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
|
IL298138A
(en)
|
2020-05-12 |
2023-01-01 |
Univ Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US12630842B2
(en)
|
2020-05-13 |
2026-05-19 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復pah基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
KR20230050336A
(ko)
|
2020-07-10 |
2023-04-14 |
인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) |
뇌전증을 치료하기 위한 방법과 조성물
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
JP2023542614A
(ja)
|
2020-08-19 |
2023-10-11 |
サレプタ セラピューティクス, インコーポレイテッド |
レット症候群の治療のためのアデノ随伴ウイルスベクター
|
|
US20250326861A1
(en)
|
2020-09-15 |
2025-10-23 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
JP2023544803A
(ja)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
Cln2疾患の眼症状に対する遺伝子療法
|
|
EP4225777A2
(en)
|
2020-10-07 |
2023-08-16 |
RegenxBio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
AU2021356684A1
(en)
|
2020-10-09 |
2023-05-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
AU2021371307A1
(en)
|
2020-10-28 |
2023-06-01 |
Regenxbio, Inc. |
VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
|
|
KR20230098176A
(ko)
|
2020-10-29 |
2023-07-03 |
리젠엑스바이오 인크. |
안구 적응증을 위한 벡터화된 tnf-알파 길항제
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
US20240018493A1
(en)
*
|
2020-11-10 |
2024-01-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Knock-in of large dna for long-term high genomic expression
|
|
AR124216A1
(es)
|
2020-12-01 |
2023-03-01 |
Univ Pennsylvania |
Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
|
|
EP4263841A1
(en)
|
2020-12-16 |
2023-10-25 |
REGENXBIO Inc. |
Method of producing a recombinant adeno-associated virus particle
|
|
US20240309076A1
(en)
|
2020-12-29 |
2024-09-19 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
|
AU2022210592A1
(en)
|
2021-01-21 |
2023-07-13 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
|
MX2023008826A
(es)
|
2021-02-01 |
2023-09-15 |
Regenxbio Inc |
Terapia génica para lipofuscinosis neuronal ceroidea.
|
|
AU2022227650A1
(en)
|
2021-02-25 |
2023-10-12 |
Celyntra Therapeutics Sa |
Compositions and methods for targeting, editing, or modifying genes
|
|
CN115197967B
(zh)
*
|
2021-04-08 |
2023-09-15 |
广州派真生物技术有限公司 |
制备重组腺相关病毒的辅助质粒及其应用
|
|
AU2022262771A1
(en)
|
2021-04-23 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
IL307902A
(en)
|
2021-04-26 |
2023-12-01 |
Regenxbio Inc |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
US20240216534A1
(en)
*
|
2021-04-26 |
2024-07-04 |
University Of Massachusetts |
Direct raav-mediated in vivo gene editing of hematopoietic stem cells
|
|
EP4334454A2
(en)
|
2021-05-04 |
2024-03-13 |
RegenxBio Inc. |
Novel aav vectors and methods and uses thereof
|
|
US20240358857A1
(en)
|
2021-05-11 |
2024-10-31 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
|
CA3223311A1
(en)
|
2021-06-18 |
2022-12-22 |
Andrea BARGHETTI |
Compositions and methods for targeting, editing or modifying human genes
|
|
US20230055381A1
(en)
|
2021-06-25 |
2023-02-23 |
Oxford Biomedica Solutions Llc |
Adeno-associated virus packaging systems
|
|
US20230090654A1
(en)
|
2021-08-24 |
2023-03-23 |
Homology Medicines, Inc. |
Adeno-associated virus formulations
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
EP4413018A1
(en)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
EP4413019A2
(en)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
EP4423285A1
(en)
|
2021-10-28 |
2024-09-04 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
WO2023077085A2
(en)
|
2021-10-29 |
2023-05-04 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the purification of adeno-associated virus
|
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
CA3238867A1
(en)
|
2021-11-29 |
2023-06-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
US20240408157A1
(en)
|
2021-12-02 |
2024-12-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
US20230323395A1
(en)
|
2021-12-15 |
2023-10-12 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
|
US20250177495A1
(en)
|
2022-01-10 |
2025-06-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
|
CN119317718A
(zh)
|
2022-01-25 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于改善心脏转导和肝脏去靶向的aav衣壳
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4486881A1
(en)
|
2022-03-01 |
2025-01-08 |
Celyntra Therapeutics SA |
Composition and methods for transgene insertion
|
|
EP4493226A1
(en)
|
2022-03-13 |
2025-01-22 |
RegenxBio Inc. |
Modified muscle-specific promoters
|
|
US20250213727A1
(en)
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
US20250249127A1
(en)
|
2022-04-14 |
2025-08-07 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
TW202417633A
(zh)
|
2022-05-03 |
2024-05-01 |
美商銳進科斯生物股份有限公司 |
用於眼適應症之載體化抗TNF-α抑制劑
|
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
EP4526884A2
(en)
|
2022-05-20 |
2025-03-26 |
Artisan Development Labs, Inc. |
Systems and methods for assessing risk of genome editing events
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
CN115948408A
(zh)
*
|
2022-09-23 |
2023-04-11 |
上海信致医药科技有限公司 |
改进的人凝血因子viii基因表达盒及其应用
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
JP2025534666A
(ja)
|
2022-10-11 |
2025-10-17 |
リジェネックスバイオ インコーポレイテッド |
操作された核酸調節エレメントならびにその使用方法
|
|
CN115896135B
(zh)
*
|
2022-11-02 |
2024-03-01 |
苏州诺洁贝生物技术有限公司 |
优化的pah基因和表达盒及其用途
|
|
EP4634394A2
(en)
|
2022-12-17 |
2025-10-22 |
The Trustees of The University of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
WO2024146935A1
(en)
|
2023-01-06 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CN116726198B
(zh)
*
|
2023-03-13 |
2024-02-13 |
陕西师范大学 |
一种抗肿瘤药物及其在脑胶质瘤治疗中的应用
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
JP2026513932A
(ja)
|
2023-04-07 |
2026-05-01 |
リジェネクスバイオ インコーポレイテッド |
組換えaav生成のための組成物及び方法
|
|
EP4694904A2
(en)
|
2023-04-13 |
2026-02-18 |
REGENXBIO Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
CN121311595A
(zh)
|
2023-04-17 |
2026-01-09 |
阿斯克生物公司 |
转基因在灵长类动物中可调节的受控表达
|
|
EP4709866A2
(en)
|
2023-05-07 |
2026-03-18 |
REGENXBIO Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2025007046A1
(en)
|
2023-06-29 |
2025-01-02 |
The Trustees Of The University Of Pennsylvania |
Mutant aav with central nervous system targeting motifs and compositions containing same
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
CN119320802A
(zh)
*
|
2023-07-17 |
2025-01-17 |
苏州吉恒基因科技有限公司 |
单链单极DNA重组腺相关病毒的cis包装元件、spAAV载体和应用
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
KR20260114566A
(ko)
|
2023-11-14 |
2026-07-22 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도
|
|
AU2024386366A1
(en)
|
2023-11-23 |
2026-06-04 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
CN121006370A
(zh)
*
|
2024-05-23 |
2025-11-25 |
深圳市深研生物科技有限公司 |
提高腺相关病毒生产效率的方法
|
|
WO2026006341A1
(en)
|
2024-06-24 |
2026-01-02 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
WO2026114267A1
(en)
|
2024-11-29 |
2026-06-04 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating alzheimer's disease in primates
|
|
EP4763209A1
(en)
|
2024-12-17 |
2026-06-24 |
Institut National de la Santé et de la Recherche Médicale |
Use of (alpha)s-setmar agonist for preventing or treating glioblastoma
|
|
WO2026151888A1
(en)
|
2025-01-08 |
2026-07-16 |
The Trustees Of The University Of Pennsylvania |
Compositions for treating friedreich's ataxia
|